Overview

Evaluation of [18F]APN-1607 as a PET Biomarker

Status:
Recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

The overall goal of this protocol is to evaluate [18F]APN-1607 as a PET radiotracer for measuring longitudinal change in tau pathology in participants with PSP.

Phase:

Phase 1

Details

Lead Sponsor:

Invicro